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Abstract 
Radioiodine has been known as an adjuvant therapy for thyroid cancer. Beside for thyroid cell, 
radioiodine is reported to be taken up by breast cell. It may be proposed as an alternative for breast 
cancer therapy. Objective: The study aim was to analyze an uptake of radioiodine and cell proliferation 
rate of breast cancer cell after the exposure of radioiodine. Methods: This study used SKBR-3 cell line 
as representative of Human Epidermal Growth Factor Receptor (HER2+) subtype. The cells were 
planted in DMEM medium added 10% fetal bovine serum (FBS), panstrep 1% and amphotericin B. The 
cells were grown until 80% confluent and then stripped. Subsequently the cells were sub-cultured on 
plates 12 and 6 wells respectively for measured uptake of radioiodine and cell proliferation rate after 
the exposure. Radioiodine uptake was calculated by sum efflux of 125 Iodine (125I) and the amount of 
uptake after the addition of 95% ethanol. Cell proliferation rate was measured by calculated by using 
clonogenic assay after iodine-131 (131I) exposure. Results: The average of iodine uptake was 194±50 
cpm/106 cell. The average cell proliferation after radioiodine exposure was 54%±5%; Conclusions: 
Radioiodine is taken by SKBR-3 cells and it reduced cell proliferation rate. This finding shows an 
opportunity for radioiodine as an alternative therapy for breast cancer. Another studies are needed 
to understand of cell death the mechanism. 
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INTRODUCTION 
Treatment of breast cancer consists of 
surgery followed by adjuvant therapy such 
as hormone therapy, radiation, 
chemotherapy and immunotherapy. The 
cost of adjuvant therapy, especially 
chemotherapy and immunotherapy can 
reach hundreds of millions.1 The financing 
of the treatment of breast cancer that 
continues to increase creates significant 
financial problems for patients and their 
families. 
The type of adjuvant therapy is determined 
by the molecular types of breast cancer. 
Each molecular type of breast cancer has a 
different prognosis and response to 
chemotherapy. The HER2+ subtype is a 
group which is sensitive to chemotherapy 
but has limited response to the therapy. It 
has a worse prognosis than the luminal 
group.2,3 Other adjuvant therapies are 
needed to increase the disease-free period 
and life expectancy for breast cancer 
patients, especially in the HER2+ subtype. 
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The ideal cancer adjuvant therapy, which is 
selective in target cells with minimal side 
effects and low prices, will make a very 
significant contribution to the 
management of breast cancer. 
Radioiodine (131I) has been used for more 
than 60 years as adjuvant therapy for 
thyroid cancer and has become an 
integrated part of its management.4 The 
therapy has increased the disease-free 
period and life expectancy in thyroid 
cancer patients with recurrent or 
metastatic cases. The ability of the thyroid 
gland to capture and maintain iodide in 
cells is the basis for the use of 131I for the 
diagnosis and treatment of thyroid 
cancer.5 SKBR-3 cell line is a breast cancer 
HER2+ subtype.  A study reported that,  
SKBR-3 cell expresses Natrium Iodide 
Symporter (NIS) which has important role 
for iodine transport cross the 
membrane.6,7 The purpose of this study is 
to analyzed an uptake of 131I and cell 
proliferation rate of SKBR-3cell after the 
exposure of 131I. 
METHODS 
SKBR-3 cell line was used in this study. The 
study was conducted at the cell culture 
Laboratory of Radioisotope and 
Radiopharmaceutical Technology (PTRR) of 
National Nuclear Body of Indonesia. SKBR-
3 cell line from ATCC (American Type 
Culture Collection). Radioiodine 125I was 
used measure the uptake and 131I was 
used to measure the toxicity.  
 
Cell Culture 
Cells were planted on 25 cm3 flask in 
DMEM medium, added 10% fetal bovine 
serum (FBS), panstrep 1% and 
amphotericin B. Cells were grown until 
80% confluent and then stripped. 
Subsequently the cells were sub-cultured 
on plates 12 and 6 well for measured 
uptake and toxicity of radioiodine.  
Measurement of Radioactive Iodine 
Uptake 
Measurements of radioiodine uptake were 
carried out by modification of methods by 
Knostnam.8 Cells were planted on 12 
culture plates, 200,000 cell/well for 24 
hours. Each well added 2µC 125I in (Hanks' 
balance salt solution) HBSS + 10mM HEPES 
(PH 7.3) and incubated at 37°C, CO2 level 
5% for one hour.  Then, the cells were 
trypsinazed and distributed in 1 mL (106 
cell)/tube. Efflux was counted every 15 
minutes until 1 hour and followed by 
incubation in 1 mL of 95% ethanol at room 
temperature for 20 minutes to release 
intracellular 125I. The uptake was calculated 
by sum of efflux calculations and the 
amount of uptake after the addition of 95% 
ethanol. The studies were carried out three 
times repeated in two separate 
experiments.   
Cell Proliferation Rate  
The toxic effect was assessed by 
clonogenic assay. It refers to the procedure 
performed by Kogai et al.9 Cells were 
planted on culture plates with 12 wells and 
wait until 80% confluent. Each well added 
1µC ml of 131I in HBSS + 10μM NaI + 10mM 
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HEPES (PH 7.3). In the control group only 
HEPES + 10MM was given (PH 7.3), then 
the cells were incubated at 37°C, with CO2 
levels of 5% for 7 hours. After the 
incubation period was complete, the cells 
were quickly washed with cold HBSS and 
were thinned with 0.05% trypsin EDTA. The 
cells were replanted on a well 6 culture 
plate with a number of 1000 cells/well. 
After ten days, the cells were washed with 
PBS, fixed and stained with a mixture of 
0.5% crystal violet in 50/50 
methanol/water for 30 minutes. Then the 
cell is washed with water and dry in room 
temperature. The next day a number of 
colonies were counted which were visible 
to the well treated and the results were 
compared to the colonies formed in well 
controls that were not given radioactive 
iodine. 
Statistical Analysis 
Data analyzed by statistic with t-test 
difference two group and using ANOVA for 
more than two group with significance 
level p<0.05. 
RESULTS AND DISCUSSIONS 
The confluent cells were incubated with 
radioiodine for an uptake and a cell 
proliferation rate analysis as shown in 
Figure 1. The mean of radioiodine uptake 
was 194±50 cpm/106 cells. The average 
cell proliferation after 131I exposure was 
54%±5% and control 99%±2%, with 
p=0.005 (Figure 2). 
 
Figure 1. SKBR-3 cell culture results with 
confluent 80%. 
 
Figure 2. Cell proliferation of SKBR3 cell after 
radioiodine was 54%±5% and control 
99%±2%, with p=0.005 
I-131 is widely used for diagnosis and 
treatment of benign thyroid diseases.10 
Rates of thyroid cancer in women with a 
history of breast cancer are higher than 
expected. Similarly, rates of breast cancer 
in those with a history of thyroid cancer are 
increased. Explanations for these 
associations include detection bias, shared 
hormonal risk factors, treatment effect, 
and genetic susceptibility.11 Thyroid and 
breast cancer are two of the malignant 
diseases with highest incidence in females. 
Based on clinical experience, breast and 
thyroid cancer often occur synchronously. 
Therefore, thyroid and breast cancer might 
share some common etiological factors.12 
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I-131 is an effective and low-risk therapy 
modality in well-differentiated thyroid 
cancer patients post near-total 
thyroidectomy. Extra thyroidal tumors 
such as breast cancer are known to be able 
to uptake 131I.13 HER2+ is one of the most 
studied tumor-associated antigens for 
cancer immunotherapy. It is 
overexpressed in various human cancers, 
such as breast.14 Up to 70-90% breast 
cancer cell expressed NIS included HER2+ 
subtype.6,15-17 NIS is a co-transporter of 
iodine to crossed cell membrane. In this 
study, SKBR-3 cell which represent HER2+ 
subtypes taken up of radioiodine. The 
exposure of radioiodine reduced cell 
proliferation significantly when is 
compared to the control cell (p=0.005). 
This finding is in line with previous study.18 
I-131 is caused DNA damage and inducing 
secondary immuno-reactivity. The effects 
of 131I on malignant cells appears to be 
depended on absorbed dose. 131I-mediated 
cellular damage, and some studies 
observed a necrotic cellular death 
following high-dose 131I treatment.19 The 
exact mechanisms of cellular death of 
SKBR3 cell have not yet been fully 
elucidated. Further studies are needed to 
uncover this issue. 
CONCLUSSIONS 
Radioiodine was taken by SKBR3 cells. Its 
exposure, reducing of cellular proliferation 
rate significantly. It may open an 
opportunity for 131I as an alternative 
therapy for breast cancer. However, cell 
death mechanism that activated after 131I 
exposure should be explored further in 
order to fully delineate the cell response. 
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